✦ LIBER ✦

Nuclear safety regulation Lessons from US experience

✍ Scribed by Victor Gilinsky

Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 754 KB
Volume: 20
Category: Article
ISSN: 0301-4215
DOI: 10.1016/0301-4215(92)90031-v

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Learning and nuclear safety: New reactor

Learning and nuclear safety: New reactors and US regulation

✍ E. Nichols; A. Wildavsky 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 746 KB

Nuclear plant safety and government regu

Nuclear plant safety and government regulation

✍ A. M. Bukrinskii; V. A. Sidorenko; N. A. Shteinberg 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 618 KB

Regulation, self-regulation and environm

Regulation, self-regulation and environmental consensus: lessons from the UK packaging waste experience

✍ Sally Eden 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB

This paper uses the case study of UK packaging waste policy to illustrate the problems of developing environmental self-regulation. In July 1993, the UK Secretary of State for the Environment `challenged' British business to organise and run a self-regulatory scheme to recover between 50 and 75 per

Incentive regulation of electricity dist

Incentive regulation of electricity distribution networks: Lessons of experience from Britain

✍ Tooraj Jamasb; Michael Pollitt 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 867 KB

This paper reviews the recent experience of the UK electricity distribution sector under incentive regulation. The UK has a significant and transparent history in implementing incentive regulation in the period since 1990. We demonstrate the successes of this period in reducing costs, prices, and en

Lessons learned from commercial experien

Lessons learned from commercial experience with nuclear plant deactivation for safe storage

📂 Article 📅 1995 🏛 Elsevier Science ⚖ 177 KB

Price regulation of drugs: Lessons from

Price regulation of drugs: Lessons from Germany

✍ Peter Zweifel; Luca Crivelli 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 944 KB

This paper purports to explain the pricing policy of pharmaceutical companies in Germany prior and after the introduction of reference prices (RP) in 1989. First, the threat of such regulation may have kept prices finite despite a completely insured market. Next, the pricing policies of both the pro